Biocon Collaborates with Voluntis on Digital Therapeutics for Insulins

 Biocon Collaborates with Voluntis on Digital Therapeutics for Insulins


  • The two companies collaborated to develop and distribute innovative digital therapeutics supporting people with diabetes on biologics therapy. The collaboration allows Biocon to offer Insulia to T2D patients across several markets globally
  • Biocon aspires to reimagine the patient ecosystem by developing a technology-dependent operating model enabling personalization of care, thus going beyond the product to reduce both the cost of the drug as well as the cost of administering the drug
  • Insulia is the US FDA cleared and CE-marked digital therapeutic with regulatory clearance to provide automated titration recommendations for all types of basal insulins. Biocon is extending the Insulia platform to its complete range of insulin products, including Recombinant Human Insulin, Insulin Glargine and Insulin Aspart, creating a digital therapeutics portfolio for patients

Click here to read full press release/ article | Ref: Biocon | Image: Medical Dialogues

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post